ViraLite: An Ultracompact HIV Viral Load Self-Testing System with Internal Quality Control

Anthony J. Politza[1], Tianyi Liu[2], Aneesh Kshirsagar[2], Ming Dong[2], Md. Ahasan Ahamed[2,6],

Muhammad Asad Ullah Khalid[6], Roland Jones[3], Uttara Seshu[4], Kathryn Risher[4], Casey N. Pinto[4,5],

Yusheng Zhu[3], and Weihua Guan[6*]

1. Department of Biomedical Engineering, Pennsylvania State University, University Park,
PA, United States

2. Department of Electrical Engineering, Pennsylvania State University, University Park, PA,
United States

3. Departments of Pathology and Laboratory Medicine and Pharmacology, Milton S. Hershey
Medical Center and Pennsylvania State University College of Medicine, Hershey, PA,
United States

4. Department of Public Health Sciences, Pennsylvania State University College of Medicine,
Hershey, PA, United States

5. The Pennsylvania State University Cancer Institute, Cancer Control Program, Hershey,
PA, United States

6. Department of Intelligent Systems Engineering, Indiana University, Bloomington, Indiana
47408

* Corresponding email address: guanw@iu.edu

Abstract

The availability of effective antiretroviral therapy has made HIV manageable, provided patients

have consistent access to routine viral load (VL) testing. Nonetheless, access to frequent VL

testing remains limited. There is a need for accessible, user-friendly testing systems that allow

people living with HIV (PLHIV) to monitor their VL more frequently and empower self-management.

Here, we developed ViraLite, a sample-to-answer, compact, accessible, and battery-powered

system for HIV viral load monitoring. The system is built upon a probe-based RT-LAMP assay

that allows for multiplexed detection and quantification. An internal quality control targeting the

RNase P was incorporated to enhance the reliability of the results. A software-reconfigurable real-

time sensing system empowered by machine learning and a smartphone-guided protocol was

developed in tandem to analyze the multiplexed assay. We analyzed 45 clinically archived

samples using ViraLite and benchmarked our results against qRT-PCR, which showed 21 positive

and 23 negative samples. Using our process control, ViraLite first identified 17 inconclusive

samples that would otherwise be classified as negative. Then, ViraLite classified 14 out of 15 HIV-

positive samples (93.3%) and 13 out of 13 HIV-negative samples (100%). The incorporation of

RNase P as a process control increased the sensitivity of ViraLite from 66.66% to 93.33%, while

maintaining a high specificity (100%). To assess the acceptance of ViraLite among PLHIV, we

recruited 480 participants from online and three clinical sites to complete a survey. Over 86% of

participants indicated ViraLite had benefits in convenience and privacy, on the other hand 61% of

participants indicated concerns with test accuracy. The integration of compact hardware, a

reliable assay, and smartphone guidance provides an accurate, easy to use system for PLHIV to

self-manage their viral load and update their prescriptions frequently.

Key Words: HIV, viral load testing, multiplex, molecular probes, LAMP, internal quality control

Introduction
50

Advances in antiretroviral therapy (ART) have reduced HIV mortality rates and lowered

transmission rates[1]. Highly active ART (HAART), a combination ART uses several individual

drugs to suppress viral replication and has been widely adopted as the clinical standard[2–4]. When

viral suppression is maintained below the detectable level, the risk of HIV transmission has been

shown to be significantly decreased[5]. Thanks to these advances, 30 million people living with HIV

(PLHIV) received treatment in 2023[6–9]. Despite advancements in treatment, HIV presents a major

public health concern due to the absence of a cure[10,11]. As a result, the number of PLHIV is

increasing as therapies continue to improve, creating demand for accurate and reliable testing to

help PLHIV maintain viral suppression. Because of the high stigma related to HIV, VL monitoring

must be highly specific, protecting the public from false positive results that lead to unnecessary

psychological distress. On the other hand, VL monitoring must maintain excellent sensitivity to

distinguish low copy numbers from false negatives, otherwise there is an increased risk for viral

transmission through patient lifestyles. Therefore, to protect public health, viral load (VL) tests

must consistently exhibit high sensitivity and specificity across diverse settings and platforms[12].

Effective viral load management hinges on chronic and precise monitoring of viral load (VL)

to maintain suppression and reduce transmission[13]. Chronic monitoring is provided from regularly

scheduled blood tests written every 3-6 months by the patient's physician[14]. These tests enable

precise monitoring of viral load by utilizing nucleic acid tests (NAT). NATs are most compatible

with VL monitoring because they offer improved sensitivity and specificity over the faster, cheaper

and more convenient alternatives, such as antigen and antibody tests[15]. NATs consist of three

stages: 1. collection, 2. preparation, and 3. Analysis [16]. For this application, HIV VL monitoring,

sample collection starts with a 3-5 mL blood sample, a requirement to produce the necessary

amount of plasma (1-3 mL) for the next step. Viral RNA extraction can be achieved using solid-

phase or liquid-phase extractions[17,18], both with similar performance, which yield isolated viral

RNA in a stabilizing buffer. Last, the number of viral RNA copies is analyzed by quantitative

polymerase chain reaction (qPCR) [19], the gold standard molecular test for quantifying nucleic

acids due to its reliability and robustness[20]. While NATs have provided very accurate and sensitive

tests for HIV VL management, the turnaround time from sample to answer can extend from

several days to weeks, severely delaying prescription updates and requiring numerous visits

[6,8,13,21–25].

To offer more convenient testing with shorter turnaround times, point of care devices aim to

bring NAT into urgent care clinics and infectious disease centers[26]. This is accomplished by

integrating all three stages of NAT into single, automated devices [27]. Several POC devices for

HIV, such as the Roche Cobas Ampliprep assay and C6000 analyzer, have been developed and

incorporated into clinical workflows. Similar assays and devices from Cepheid and Abbott provide

comparable performance and throughput for HIV clinics [28]. These devices significantly reduce the

turnaround times of traditional lab-based NAT. However, the convenience of these devices is

mainly witnessed in the laboratory, providing higher throughput with less hands-on time. The

sample volumes required pose a significant challenge to patient convenience and comfort, as a

venous blood draw is still necessary. Therefore, these devices are not well-suited to improve

patient convenience in healthcare centers.

To improve the convenience of HIV VL monitoring, several studies have focused on

developing devices for at-home testing by utilizing reduced sample volumes and miniaturized

electronics. Finger prick blood has been validated as a testing sample for HIV, but the small

volumes involved (25-100 µl) require very high sensitivity and robust sample preparation.

Successful at-home testing devices offer semi-automated workflows from finger prick blood using

magnetic beads and PCR detection. However, these devices are not ideal for accessible testing

due to the requirements of PCR and reliance on lab infrastructure. Loop mediated isothermal

amplification (LAMP) [29] offers an alternative to PCR, offering comparable sensitivity and reaction-

times[30]. Some devices have successfully implemented LAMP assays toward at-home or portable

testing for a variety of infectious diseases and environmental monitoring. Our previous works [31–

34] demonstrated the speed and sensitivity of LAMP for HIV VL monitoring but identified the need

for specific readout methods of LAMP to resolve the outstanding issues such as false positives
and lack of multiplexing to rival PCR [35,36]. Multiplexing is needed for at-home tests using LAMP to
enable internal quality control monitoring to mimic conventional PCR assays that implement
multiplex controls to consistently demonstrate high sensitivity and specificity[37,38], a requirement
for VL monitoring to safeguard public health [39]. There is an unmet need for an HIV multiplexed
RT-LAMP assay that uses internal quality controls for consistently high sensitivity and specificity
toward at-home VL monitoring for people living with HIV (PLHIV).
Here in this work, we present ViraLite, an ultracompact HIV VL system utilizing multiplexed
RT-LAMP to introduce internal quality controls for personal testing. Our device provides an easily
accessible, user-guided test by implementing multiplex LAMP, semi-automated electronics, and
smartphone assistance. The system is built upon a probe-based, multiplexable reverse-
transcriptase-loop-mediated isothermal amplification (RT-LAMP) assay which enables reliable
processing control and VL quantification. A versatile, and scalable sensing system empowered
by machine learning (ML) was also developed alongside the multiplex assay. From 50 µl of
plasma, the smartphone-guided system can detect HIV and RNase P (a process control) in a
multiplexed reaction. We analyzed 45 clinically archived samples using ViraLite and benchmarked
our results against qRT-PCR, which showed 21 positive and 23 negative samples. With our
process control, we identified 17 inconclusive samples that would otherwise be classified as
negative. Then, ViraLite classified 14 out of 15 HIV-positive samples (93.3%) and 13 out of 13
HIV-negative samples (100%), demonstrating the need for process control incorporation with RT-
LAMP assays. Using this approach improved the sensitivity of ViraLite from 66.66% to 93.33%,
while maintaining a high specificity (100%). To assess the usability and acceptance of ViraLite
among PLHIV, we recruited 480 participants from online and three clinical sites to complete a
survey. ViraLite showed strengths in Convenience and Privacy with over 86% of participants
indicating benefits in these areas. On the other hand, participants identified test Accuracy (61%)
as the largest concern to using our system. By integrating compact hardware, a reliable assay,
and smartphone guidance, ViraLite offers an accurate and user-friendly system for PLHIV to self-
manage their viral load and frequently update their prescriptions.
131
132   **Results**
133
134   **ViraLite Workflow**
135
To enable at home use, we designed and validated a portable sample-to-answer platform for
nucleic acid testing (**Figure 1a**). We previously validated the use of plasma separation

membranes[32] to collect samples and light-weight centrifuges for portable RNA extraction[40],

therefore enabling us to develop a fully portable system. A smartphone app will guide the user

through each stage: Sample Collection, RNA Extraction, and Amplification (See **Supplementary**

Video S1). Last, the extracted sample will be detected using our new multiplex RT-LAMP assay.

This assay uses custom designed probes to enhance the specificity of each assay for use in

multiplex format (**Figure *1*b-c**). ViraLite maintains a minimal packed footprint (**Figure *1*d**), and

introduces our next generation of fluorescence analyzer, showcasing a machine learning pipeline

that uses a multi-spectral color chip to empower one-pot multiplexing (**Figure *1*e**). Amplification

is conducted on ViraLite to provide real-time updates to the user through the Bluetooth connected

app.

HIV RT-LAMP Assay with Internal Quality Control

To create an internal quality-controlled HIV assay, we designed two probe-based LAMP

assays (**Supplementary Information**). We explored both assays in single-plex format before

migrating into a one-pot multiplex assay (**Supplementary Figure S1**). The HIV RT-LAMP assay

targets the Reverse-Transcriptase sub-region of the HIV genome and demonstrated a LOD of 21

copies (95% CI) (**Supplementary Figure S1a**). The RNase-P RT-LAMP assay targets the mRNA

strand 'RPP subunit p20' and demonstrated a LOD of 10 copies using a 95% confidence level

(**Supplementary Figure S1b**). Both assays showed very strong correlation between benchtop

and portable devices, suggesting suitable deployment into multiplex format (**Supplementary**

Figure S2a-b).

To evaluate the cross-reactivity between our RT-LAMP assays and target samples, we

analyzed the assay against three possible sample variations to measure specificity. We examined

three scenarios: HIV and RNase P positive (to simulate viral rebound), only RNase P positive (to

simulate a patient without viral rebound), and a No-target-control (NTC, to simulate an invalid

test). Each sample was tested in triplicate using a one-pot multiplex assay**.** For each of these

samples we found that only the appropriate target to channel relationship showed detection. For

example, sample 1 showed both HIV and RNase P detection (**Figure 2a**). On the other hand,

sample 2 showed only RNase P was detected. Sample 3 (a No Target Control) showed no

detection for either target, demonstrating strong specificity and no primer interactions. These

results were identical when tested using the ViraLite analyzer (**Supplementary Figure S3**). From

these results we demonstrate that our multiplex assay is robust and capable of multiplex detection

in clinically relevant scenarios.

To investigate the limit of detection (LOD) of our multiplexed LAMP, we analyzed the multiplex
assay with HIV-1 samples ranging from 10^5 copies down to 10 copies per reaction. As shown in
Figure 2b, the multiplexed assay performed similarly to the single plex assay showing a
reasonable R^2 of 0.80 over the range of concentrations detected. The assay also showed a LOD
of 47 copies. These results suggest that our assay has the potential for semi-quantitative abilities
for HIV and can be used to process 100 µl samples which could contain concentrations as low as
1 cp/µl (1000 cp/mL). Next, we examined the RNase P with an identical range of RNA
concentrations (10^5 to 10 cp/rxn) (**Figure 2c**). The multiplex assay showed similar performance
to its single-plex counterpart for RNase P showing strong linearity (R^2 = 0.82). Following a hit
curve analysis, we found the LOD of the multiplex assay for RNase P was 351 copies. Despite a
higher sensitivity than anticipated, we still expect our multiplex assay to detect RNase P from
plasma samples (~12 cp/µl) (**Supplementary Figure S4**). Given a finger prick sample between
50-100 µl, we expect between 600-1200 copies, a value well above our multiplex LOD for RNase
P. These results demonstrate our multiplex assay's ability to be used for the quantitative detection
of two targets simultaneously. Therefore, we can expect our assay to maintain high sensitivity
and specificity when examining clinical samples using a portable device
188
189   **Validation of Multiplex Detection**
190
To achieve a compact diagnostic device capable of multiplexed detection, we trained, tested,
and integrated a neural network that converts 8-channel fluorescence into dye concentrations
(FAM and HEX). Our previous study showed that a neural network worked best to clarify signal
from overlapping emission spectra[41] (**Supplementary Figure S5**), therefore enabling our device
to be battery powered, lightweight, and easy to use while maintaining a highly accurate optical
setup (**Figure 3a**)[31,33,34,42,43]. To evaluate the machine learning model's accuracy, we examined
the analyzer's optical detection using synthetic dyes and real-time LAMP assays. We prepared
six concentrations of FAM and HEX dye (0, 0.2, 0.4, 0.6, 0.8, 1 µM) across 36 potential
combinations and collected ten data points per combination, replicated four times, and split into
80/20% for training and testing. We found our model performed very well demonstrating very
strong linearity for both FAM (R^2 = 0.994) and HEX (R^2 = 0.996) across all combinations (**Figure**
3b). These results suggest our analyzer's optical module and machine learning algorithm are well
suited for the multiplex analysis of real-time LAMP assays. To verify the analyzer's real-time
sensitivity, we conducted several amplification assays on the device. In addition, we duplicated
the assays to be operated in parallel on the benchtop thermal cycler. In **Figure 3c**, we found that

the portable analyzer showed great agreement with the benchtop device for both HIV (r = 0.985)
and RNase P (r = 0.962) detection across a range of concentrations. Strong linearity and more
than 96% agreement with the benchtop analyzer suggests our device is highly accurate,
reproducible, and robust. These features make our device well suited for portable analysis of
multiplex assays. Further validation of our device is needed to examine its performance detecting
clinical plasma samples.

Deploying ViraLite for Qualitative testing

To validate our analyzer's qualitative performance, we examined its clinical sensitivity and
specificity using 45 plasma samples. Each sample was divided into two equal aliquots of 50 µl.
One sample was prepared and analyzed using typical laboratory protocol (centrifuge & qRT-PCR)
(**Figure 4a**). The second aliquot was prepared and analyzed using our portable extraction
methods and analyzed using our multiplex RT-LAMP analyzer (**Figure 4b**). These results are
summarized in **Figure 4c** to provide qualitative analysis (data shown in **Supplementary Table**
S1). Our PCR results indicated 21 positive and 24 negative samples respectively. Initially, our
RT-LAMP results identified 15 positive and 30 negative samples, demonstrating a relatively poor
sensitivity (66.66%) but high specificity (100%). However, the advantage of our internal quality
control-based LAMP assay enables us to remove invalid tests, samples where no RNase P is
detected. Regardless of HIV detection, a sample will be deemed invalid if no RNase P is detected.
Removing these samples reduced our data set to 15 positive and 13 negative samples. As a
result, our RT-LAMP performance greatly improves from 66.66% sensitivity to 93.33% as we
identify 14 positive and 13 negative samples (**Figure 4d**). The specificity of our assay remained
100%. With a sensitivity of 93.33% and 100% specificity, we demonstrate our analyzer's strong
qualitative ability for classifying clinical samples.

Deploying ViraLite for Semi-Quantitative testing

To demonstrate ViraLite's usability for semi-quantitative viral load monitoring, we classified
each sample using qRT-PCR and our RT-LAMP. To achieve this, we used the clinically
recommended threshold, 1000 cp/mL [1,20,44–47], to classify each sample using qRT-PCR C_q and
RT-LAMP T_p. This was established using five reference concentrations for both PCR and RT-
LAMP (dashed lines in **Figure 4a-b**) to create two classes: Above and Below. The classification
is summarized in **Figure 4e**. These reference concentrations showed much smaller standard

deviations compared to actual samples because they were tested using purified HIV RNA versus
extracted RNA from actual samples. Our analyzer identified 10 'above' and 18 'below' samples,
whereas qRT-PCR classified 8 'above' and 20 'below'. Comparing the analyzer's T_p against the
C_q from benchtop PCR (Figure 4f), we found our analyzer accuracy to be 86% and our overall
quantitative ability showed 84% agreement with the benchtop device. These results are expected
since our multiplex RT-LAMP assay shows an order of magnitude higher LOD than the typical
qRT-PCR assay (1-10 cp/rxn). We expect that further improvements to this assay could boost its
analytical sensitivity and therefore improve the overall accuracy for quantification. Currently, our
analyzer boasts 93.33% sensitivity and 100% specificity, showcasing the capability and need for
internal quality-controlled RT-LAMP assays. With an accuracy of 86% and 84% agreement with
benchtop qRT-PCR, ViraLite demonstrates a capability for semi-quantitative viral load monitoring.

Surveying ViraLite perception among patients in HIV clinics.

To evaluate the potential acceptance and usability of our system, we surveyed 480 patients
on HIV or PrEP treatment. Voluntary patients at several HIV clinics were asked to watch a short
video (**Supplementary Video S2**) showing the steps to operate ViraLite. After watching the video,
patients were asked a series of demographic and response questions. In **Figure 5a-f** we
summarized the patient demographics using gender, age, income, education level, urban/rural,
and race. These demographics align with the 2023 U.S. Statistics for HIV, suggesting a
widespread and unbiased survey (**Supplementary Information**) [48]. Next, survey responses were
categorized by the treatment plan, HIV antiretroviral therapy or pre-exposure prophylaxis (PrEP)
(**Figure 5g**). We found that 55.6% of patients were on HIV treatment and the remaining 44.4% of
patients were on PrEP. More than half of participants receiving HIV treatment indicated
Convenience, Privacy, Confidentiality, and Time Saved as their most perceived benefits (**Figure
5h**). Participants on PrEP were more interested in benefits associated with Time Saved,
[decreased risk of] Transmission, and Privacy. Less than 50% all participants were interested in
the benefits of Time to results and Cost. On the other hand, survey participants on HIV treatment
were most concerned with Accuracy, Guidance, and Prescription (**Figure 5i**). Patients receiving
PrEP showed highest concern with Prescription [management], Misinterpretation [of results],
Accuracy, and Guidance. Less than half of all participants were concerned with Emotional Impact
[of tests/results], Record Keeping, or Cost. These results suggest that participants are deeply
interested in tests that bridge the gap between clinic care and at home testing; however, they are
concerned about the accuracy and guidance of ViraLite. Notably, the 'Cost' of the device was

neither a major benefit nor concern for people, suggesting the usefulness of at home monitoring
outweighs the potential costs of ownership. Concerns over prescription management may
suggest that patients are unsure how at-home testing will affect their prescription. This is an
interesting topic area we will further develop alongside ViraLite. Overall, ViraLite agreement with
survey feedback suggests there is high potential for immediate positive impact on patients. At the
same time, the future development of ViraLite will heavily consider concerned areas as we
attempt to translate this technology into patients' hands.

Discussion
283

To summarize, the number of PLHIV is expected to rise in the coming decade due to
advancements in ART, increasing the need for effective VL management[4,14,49]. Newly developed
HIV VL monitoring tests should ideally demonstrate excellent clinical sensitivity and specificity to
protect both patient and public health[50,51]. This is best achieved through timely & convenient
testing to encourage patients and empower self-management[28]. However, large sample volumes
and lab infrastructure remain key challenges for accessible VL monitoring[26]. To address these
issues, there is a need for portable, sensitive, and specific assays to bring convenient VL
monitoring closer to patients.

A key innovation of our ViraLite system is its high sensitivity and specificity, achieved through
our probe-based RT-LAMP assay. When analyzing 45 clinically archived plasma samples, our
system demonstrated 93% clinical sensitivity and 100% clinical specificity. This was accomplished
by combining two sensitive RT-LAMP assays (HIV and RNase P) into a single-pot reaction. Unlike
traditional RT-LAMP, relying on turbidity or intercalating dyes[52,53], our probe-based approach
detects fluorescent signal generated from a specific molecular probe, like PCR assays[54]. This
approach allows us to improve clinical sensitivity by pre-classifying inconclusive samples that
might otherwise be negative, using the RNase P internal quality control. In addition, the probe-
based design effectively eliminates false positives, ensuring reliable VL monitoring from a portable
device. A survey of potential users revealed that 86% believe it would improve testing
convenience and privacy, aligning with our intended goals. However, 61% expressed concerns
about test accuracy, prescription management, and guidance, indicating areas for future
improvement.

A second key innovation is the development of a portable testing platform for HIV VL
monitoring, enhanced by machine learning, battery-powered devices, and smartphone
connectivity. A single-pot multiplex assay with two fluorophores presents a complex sensing

challenge for point of care devices. In our previous devices, a color sensor reads the emitted light

from fluorophores within a bulk assay which works well when concentrations are sufficiently

high[31,32,42,43]. However, multiplexing presents significantly more challenges with multiple excitation

sources and emission filters for detecting multi-fluorophore arrangements[41]. We addressed this

issue by using a multi-spectra color sensor linked to a machine learning model, which translates

sensor data into fluorophore concentration. This solution allows us to maintain a simple and cost-

effective optical setup, with all electronics housed in handheld, battery-powered devices. Real-

time data can be transferred wirelessly between the device and a connected smartphone for

update to date results.

ViraLite demonstrates a proof-of-concept system, offering a rapid and sensitive assay well

suited for resource-limited point-of-care settings. However, to fully realize a personal VL

management system, several improvements are needed to minimize the user interaction and

increase robustness. Sample preparation remains a significant challenge for compact sensitive

point of care devices, particularly for plasma separation from blood and extracting viral RNA is

challenging for small microfluidic devices aimed at patient convenience[25,55]. While previous

studies explored automated methods using magnetic beads and microfluidics, we chose to utilize

semi-automated solid-phase extraction using a portable centrifuge for its increased efficiency,

even at low sample concentrations[40]. Future advancements in centrifugal microfluidics could

enable fully integrated sample preparation, directly delivering viral RNA into multiplexed RT-LAMP.

Finally, our study did not incorporate lyophilization for our RT-LAMP assay. In our previous study,

we showed that lyophilization can be achieved without significant degradation[32]. Therefore, these

areas are an active area of investigation to improve device size, user interaction, and system

robustness.

The ViraLite system presented here enables highly sensitive, portable, self-testing that is

empowered by multiplex RT-LAMP, machine learning, and semi-automated, battery-powered

electronics. ViraLite demonstrates the seamless integration of sample preparation, multiplex

LAMP detection, and smartphone guidance for an accessible testing system for HIV VL

monitoring. Probe-based RT-LAMP enables multiplexed assays to rival PCR assays in detection

and monitoring clinical samples. Machine learning empowers ViraLite to use simple, off-the-shelf

optical components for accurate quantification of one-pot multiplex assays. Clinical validation with

clinically archived plasma samples demonstrated the real-world application of ViraLite's by

coupling reliable clinical data with easy to access, portable hardware. Survey participants

reassured us of our target demographic and gave us defined areas of improvement. In summary,

ViraLite introduces a viable monitoring system to translate VL management outside of clinics and

into accessible, comfortable locations. The conveniency of our system has the potential to rapidly
change the frequency of VL monitoring, offering improved ART, decreased transmission, and
advanced drug development.
345
346 **Materials and Methods**
347
Multiplex RT-LAMP assay. The RT-LAMP assay reaction, optimized for the detection of HIV-1,
involves a reaction mix with a total volume of 25 µl. The assay (shown in Supplementary Table
S2) contains an isothermal buffer, which includes Tris-HCl, $(NH_4)_2SO_4$, KCl, $MgSO_4$, Tween 20,
and dNTPs, along with *Bst*, PCR grade H_2O and $MgSO_4$ (6 mM) were also included in the reaction
mixture. RNA template was added in addition to primers, consisting of 0.2 µM of F3 and B3, 1.6
µM of FIP and BIP, and 0.8 µM of LPF and LPB. The reaction was performed at 60 ℃ for a
duration of 60 minutes. For the multiplexed assay, the primer concentrations were reduced to a
ratio of 3:2 HIV to RNase P. The HIV primer concentrations were 0.15 µM F3 and B3, 1.2 µM FIP
and BIP, 0.4 µM Fd and QFIP, and 0.6 µM LF and LB. The RNase P primer concentrations are
0.1 µM F3 and B3, 0.8 µM FIP and BIP, 0.4 µM LFP, Q and LB. All RT-LAMP primers and probes
are listed in Supplementary Table S3.
359
qRT-PCR Assay. The PCR HIV assay was previously validated by Palmer et al. [54] (See
Supplementary Table S4). The total PCR volume consisted of 25 µL: 6.25 µL of Fast Taq One-
Step Master Mix (Applied Biosystems, Waltham, MA), 1.5 µL of Forward and Reverse primer,
0.63 µL of Probe, 10 µL of extracted RNA sample, and 5.13 µL of Nuclease-free water (New
England Biolabs, Ipswich, MA). Analysis was conducted using a Bio-Rad C1000 Thermal Cycler
(Hercules, CA). Thermal Cycling was set as 50 °C for 5 min, 95 °C for 3 s, 65 °C for 30s, and
repeated 60×. Primers and probes were purchased from Integrated DNA Technologies (Coralville,
IA). Positive samples were identified and tagged with a quantitative cycle (C_q) value when the
background RFU reached a threshold defined as: $\mu + 3\sigma$.
369
ViraLite instrumentation. The analyzer was designed using PTC Creo software and 3D-printed
using a Method X printer from MakerBot system. The printed circuit boards (PCB) were designed
using Autodesk Eagle and manufactured by OSH Park. Laboratory personnel soldered individual
electronic components and the Microcontroller Unit (MCU) onto the PCB. The thermal module
consists of a resistive-heating element (PWR263S-20-2R00J, Digi-Key) attached to the underside
of the aluminum heating block using thermal compound (AATA-5G, Artic Alumina). Temperature

feedback is provided from within the core of the heating block by a thermistor (95C0606, Digi-
Key). Sustained temperature for extended periods of time was achieved using negative feedback
control through an N-channel power Metal-Oxide-Semiconductor Field-Effect Transistor
(MOSFET) (63J7707, Digi-Key). The optical module was designed using an adjustable Res
Cermet Trimmer (3296W, Digi-Key) for LED intensity control, a wide spectrum IC Color Sensor
(AS7341, Digi-Key) for optical detection, and a blue SMD LED (1497-1138-1, Digi-Key) for
fluorescence excitation. An I^2C multiplexer was used as the expander for the sensor. The
smartphone graphical user interface (GUI) software was developed using MIT App Inventor. The
GUI facilitates control and communication with the device via Bluetooth (**Supplementary Figure**
S6a-b). A Bill of Materials for the analyzer is included as **Supplementary Table S5**.
386
Sample preparation with portable device. Portable extractions were achieved using the Viral
RNA Mini kit from Qiagen. Following our previously established protocol[40], extractions were
performed with 50-100 µl sample, 500 µl AVL Buffer, 500 µl 95% Ethanol, 500 µl Wash Buffer I,
500 µl Wash Buffer II, 500 µl 95% Ethanol, and 80 µl water. During all extraction stages the
portable device runs at max speed (6000 rpm/ 1743 rcf.). Our smartphone app will guide a user
through the process of this extraction (Seen in Supplementary Video S1).
393
394 **Sample preparation with benchtop device.** Benchtop extractions were conducted according to
395 the Viral RNA Mini kit from Qiagen. Extractions were performed with 100-140 µl sample, 500 µl
396 AVL Buffer, 500 µl 95% Ethanol, 500 µl Wash Buffer I, 500 µl Wash Buffer II, 80 µl water[40]. The
397 benchtop centrifuge was set to 1 min. at 6000 rcf. for all steps except Wash Buffer II where the
398 centrifuge was operated for 3 min. at 20,000 rcf.
399
Clinical Samples. Plasma samples were collected from HIV patients treated at the Penn State
Hershey Medical Center following controlled standard operating procedure. Investigational
Review Board (IRB) approval was provided by the Pennsylvania State University
(STUDY00015905). The samples were de-identified and randomly selected from remnant plasma
batches. No identifiable data was recorded or transferred between study locations. For each test,
50 µl of clinical plasma sample was used.
406
Survey recruitment. Survey participants were recruited online and at the Penn State Hershey
Medical Center, the UPMC infectious disease center, the Penn Health Lancaster General Health
Comprehensive Care Center, Seattle King County HIV/STI clinics (Seattle, Washington), and the

Washington University HIV/STI clinics (St. Louis, Missouri). In total 1200 surveys were collected
from all site locations. We discarded any survey which did not watch more than 30s of the video,
therefore excluding 720 respondents, leaving 480 respondents. Institutional Review Board (IRB)
approval was provided by the Pennsylvania State University (STUDY00024241). Participants
were compensated with a $10 Amazon gift card for the successful completion of the survey.
415
Statistical analysis. All data processing and figure generation were completed using Python.
Data is displayed as the mean of triplicates plus or minus three standard deviations, unless
otherwise noted. Positive samples are classified using Time to Positive (T_p) or quantitative cycle
(C_q) when RFU reaches a threshold of $\mu + 3\sigma$. LOD was calculated with 95% confidence using a
logistic function fit to the hit rate for each assay. Correlation and linearity were computed using
SciPy and least squares regression.
422

Acknowledgments
This work was partially supported by the National Institutes of Health (R61AI147419,
R33AI147419), and the National Science Foundation (1912410, 2319913). Any opinions, findings,
conclusions, or recommendations expressed in this work are those of the authors and should not
be construed to represent any official NIH and NSF or U.S. Government determination or policy.

Declarations
The authors declare the following competing financial interest(s): A provisional patent has been
filed related to the technology described herein.
432

Author Contributions
Anthony J. Politza: conceptualization, software, investigation, writing – original draft. **Tianyi Liu**:
conceptualization, resources, writing – review & editing. **Aneesh Kshirsagar**: conceptualization,
resources, writing – review & editing. **Ming Dong**: methodology, supervision, visualization, writing
– review & editing. **Md. Ahasan Ahamed**: visualization, writing – review & editing. **Muhammad**
Asad Ullah Khalid: supervision, writing – review & editing, project management. **Roland Jones**:
resources, methodology, and investigation. **UttaraSeshu**: formal analysis, data curation, writing
– review & editing. **Kathryn Risher**: formal analysis, data curation, writing – review & editing.
Casey N. Pinto: data curation, project administration, supervision, writing – review & editing.
Yusheng Zhu: investigation, methodology, resources, supervision. **Weihua Guan**:
conceptualization, supervision, writing – review & editing, project administration, and funding
acquisition.

References

1. Eisinger, R. W., Dieffenbach, C. W. & Fauci, A. S. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. *JAMA* **321**, 451–452 (2019).

2. Davey, R. T. *et al.* HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. *Proc. Natl. Acad. Sci.* **96**, 15109–15114 (1999).

3. Amor, A. *et al.* Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. *AIDS* **20**, 1460 (2006).

4. J Buzón, M. *et al.* HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. *Nat. Med.* **16**, 460–465 (2010).

5. Tanser, F., Bärnighausen, T., Grapsa, E., Zaidi, J. & Newell, M.-L. High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa. *Science* **339**, 966–971 (2013).

6. Chamie, G., Napierala, S., Agot, K. & Thirumurthy, H. HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan Africa. *Lancet HIV* **8**, e225–e236 (2021).

7. Stevens, W., Gous, N., Ford, N. & Scott, L. E. Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. *BMC Med.* **12**, 1–8 (2014).

8. Stevens, W. S. & Marshall, T. M. Challenges in implinting HIV load testing in South Africa. *J. Infect. Dis.* **201**, S78–S84 (2010).

9. Wang, H. *et al.* Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. *Lancet HIV* **3**, e361–e387 (2016).

10. UNAIDS. Global HIV & AIDS statistics — Fact sheet. https://www.unaids.org/en/resources/fact-sheet.

11. WHO. Summary of the Global HIV epidemic. https://www.who.int/data/gho/data/themes/hiv-aids (2023).

12. Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. *Nat. Rev. Dis. Primer* **1**, 1–22 (2015).

13. Drain, P. K. *et al.* Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable Global HIV/AIDS Response. *Clin. Microbiol. Rev.* **32**, 10.1128/cmr.00097-18 (2019).

14. Peter, T. *et al.* Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. *Lancet Infect. Dis.* **17**, e26–e29 (2017).

15. Niemz, A., Ferguson, T. M. & Boyle, D. S. Point-of-care nucleic acid testing for infectious diseases. *Trends Biotechnol.* **29**, 240–250 (2011).

16. Li, M. *et al.* Nucleic Acid Tests for Clinical Translation. *Chem. Rev.* **121**, 10469–10558 (2021).

17. Wierucka, M. & Biziuk, M. Application of magnetic nanoparticles for magnetic solid-phase
extraction in preparing biological, environmental and food samples. *TrAC Trends Anal. Chem.*
59, 50–58 (2014).

18. Lee, S. M., Balakrishnan, H. K., Doeven, E. H., Yuan, D. & Guijt, R. M. Chemical Trends in
Sample Preparation for Nucleic Acid Amplification Testing (NAAT): A Review. *Biosensors* **13**,
980 (2023).

19. Piatak, M. *et al.* High Levels of HIV-1 in Plasma During All Stages of Infection Determined By
Competitive PCR. *Science* **259**, 1749–1754 (1993).

20. Saag, M. S. *et al.* HIV viral load markers in clinical practice. *Nat. Med.* **2**, 625–629 (1996).

21. Stevens, W., Gous, N., Ford, N. & Scott, L. E. Feasibility of HIV point-of-care tests for
resource-limited settings: challenges and solutions. *BMC Med.* **12**, 173 (2014).

22. Shafiee, H. *et al.* Emerging Technologies for Point-of-Care Management of HIV Infection.
Annu. Rev. Med. **66**, 387–405 (2015).

23. Schito, M. *et al.* Opportunities and Challenges for Cost-Efficient Implementation of New Point-
of-Care Diagnostics for HIV and Tuberculosis. *J. Infect. Dis.* **205**, S169–S180 (2012).

24. Pai, N. P. *et al.* Head-to-head comparison of accuracy of a rapid point-of-care HIV test with
oral versus whole-blood specimens: a systematic review and meta-analysis. *Lancet Infect.*
Dis. **12**, 373–380 (2012).

25. Jangam, S. R., Agarwal, A. K., Sur, K. & Kelso, D. M. A point-of-care PCR test for HIV-1
detection in resource-limitedsettings. *Biosens. Bioelectron.* **42**, 69–75 (2013).

26. Dorward, J., Drain, P. K. & Garrett, N. Point-of-care viral load testing and differentiated HIV
care. *Lancet HIV* **5**, e8–e9 (2018).

27. Sloma, C. R. *et al.* Comparison of the Abbott RealTime Human Immunodeficiency Virus Type
1 (HIV-1) Assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test: Workflow, Reliability,
and Direct Costs. *J. Clin. Microbiol.* **47**, 889–895 (2009).

28. Mariani, D. *et al.* The performance of a new point-of-care HIV virus load technology to identify
patients failing antiretroviral treatment. *J. Clin. Virol.* **122**, 104212 (2020).

29. Notomi, T. *et al.* Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* **28**, e63
(2000).

30. Tomita, N., Mori, Y., Kanda, H. & Notomi, T. Loop-mediated isothermal amplification (LAMP)
of gene sequences and simple visual detection of products. *Nat. Protoc.* **3**, 877–882 (2008).

31. Liu, T. *et al.* Fingerpick Blood-Based Nucleic Acid Testing on A USB Interfaced Device
towards HIV self-testing. *Biosens Bioelectron* **209**, 114255 (2022).

32. Liu, T., Politza, A. J., Kshirsagar, A., Zhu, Y. & Guan, W. Compact Point-of-Care Device for
Self-Administered HIV Viral Load Tests from Whole Blood. *ACS Sens.* **8**, 4716–4727 (2023).

33. Choi, G., Prince, T., Miao, J., Cui, L. & Guan, W. Sample-to-answer palm-sized nucleic acid
testing device towards low-cost malaria mass screening. *Biosens. Bioelectron.* **115**, 83–90
(2018).

34. Choi, G. *et al.* A field-deployable mobile molecular diagnostic system for malaria at the point
of need. *Lab. Chip* **16**, 4341–4349 (2016).

35. Dong, M., Kshirsagar, A., Politza, A. J. & Guan, W. High Fidelity Machine-Learning-Assisted
False Positive Discrimination in Loop-Mediated Isothermal Amplification Using Nanopore-
Based Sizing and Counting. *ACS Nano* **18**, 7170–7179 (2024).

36. Rolando, J. C., Jue, E., Barlow, J. T. & Ismagilov, R. F. Real-time kinetics and high-resolution
melt curves in single-molecule digital LAMP to differentiate and study specific and non-specific
amplification. *Nucleic Acids Res.* **48**, e42 (2020).

37. Rosenstraus, M., Wang, Z., Chang, S.-Y., DeBonville, D. & Spadoro, J. P. An Internal Control
for Routine Diagnostic PCR: Design, Properties, and Effect on Clinical Performance. *J. Clin.*
Microbiol. **36**, 191–197 (1998).

38. Hoorfar, J. *et al.* Practical Considerations in Design of Internal Amplification Controls for
Diagnostic PCR Assays. *J. Clin. Microbiol.* **42**, 1863–1868 (2004).

39. Bourlet, T. *et al.* HIV-1 Load Comparison Using Four Commercial Real-Time Assays. *J. Clin.*
Microbiol. **49**, 292–297 (2020).

40. Politza, A. J. *et al.* Development and validation of a portable device for lab-free versatile
nucleic acid extraction. *BioTechniques* 1–11 (2024) doi:10.1080/07366205.2024.2427544.

41. Kshirsagar, A., Politza, A. J. & Guan, W. Deep Learning Enabled Universal Multiplexed
Fluorescence Detection for Point-of-Care Applications. *ACS Sens.* (2024)
doi:10.1021/acssensors.4c00860.

42. Kshirsagar, A. *et al.* Handheld Purification-Free Nucleic Acid Testing Device for Point-of-Need
Detection of Malaria from Whole Blood. *ACS Sens.* **8**, 673–683 (2023).

43. Tang, Z. *et al.* SLIDE: Saliva-Based SARS-CoV-2 Self-Testing with RT-LAMP in a Mobile
Device. *ACS Sens.* **7**, 2370–2378 (2022).

44. Farzadegan, H. *et al.* Sex differences in HIV-1 viral load and progression to AIDS. *The Lancet*
352, 1510–1514 (1998).

45. Wilson, D. P., Law, M. G., Grulich, A. E., Cooper, D. A. & Kaldor, J. M. Relation between HIV
viral load and infectiousness: a model-based analysis. *The Lancet* **372**, 314–320 (2008).

46. Phillips, A. N. *et al.* HIV Viral Load Response to Antiretroviral Therapy According to the
Baseline CD4 Cell Count and Viral Load. *JAMA* **286**, 2560–2567 (2001).

47. Calmy, A. *et al.* HIV Viral Load Monitoring in Resource-Limited Regions: Optional or
Necessary? *Clin. Infect. Dis.* **44**, 128–134 (2007).

48. HIV & AIDS Trends and U.S. Statistics Overview. *HIV.gov* https://www.hiv.gov/hiv-
basics/overview/data-and-trends/statistics.

49. Johnson, C. C. *et al.* To err is human, to correct is public health: a systematic review examining
poor quality testing and misdiagnosis of HIV status. *J. Int. AIDS Soc.* **20**, 21755 (2017).

50. Drain, P. K. *et al.* Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable
Global HIV/AIDS Response. *Clin. Microbiol. Rev.* **32**, 10.1128/cmr.00097-18 (2019).

51. Hayes, R. J. *et al.* Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071
(PopART). *N. Engl. J. Med.* **381**, 207–218 (2019).

52. Nagamine, K., Hase, T. & Notomi, T. Accelerated reaction by loop-mediated isothermal
amplification using loop primers. *Mol. Cell. Probes* **16**, 223–229 (2002).

53. Curtis, K. A. *et al.* A multiplexed RT-LAMP assay for detection of group M HIV-1 in plasma or
whole blood. *J. Virol. Methods* **255**, 91–97 (2018).

54. Palmer, S. *et al.* New real-time reverse transcriptase-initiated PCR assay with single-copy
sensitivity for human immunodeficiency virus type 1 RNA in plasma. *J. Clin. Microbiol.* **41**,
4531–4536 (2003).

55. Guichet, E. *et al.* Comparison of different nucleic acid preparation methods to improve specific
HIV-1 RNA isolation for viral load testing on dried blood spots. *J. Virol. Methods* **251**, 75–79
(2018).

 Figures and Legends

Figure 1. Demonstration of portable VL monitoring for self-management using the ViraLite protocols. a) Samples are first gathered using a plasma separation card that filters finger-prick blood and traps plasma into an absorption layer. Next, that layer is transferred to lysis buffer and RNA extraction is conducted using our lab developed portable centrifuge to process QIAamp viral RNA extractions. Last, the isolated RNA is added to our multiplex RT-LAMP assay for real-time analysis using our portable analyzer. b) The HIV-1 components of the multiplex assay target the reverse-transcriptase sub-region of the viral genome. A designed probe, using the FIP primer attached with a quencher, incorporates into the reaction as amplicons are generated and creates a change in fluorescence as a complementary fluorophore is released into the bulk assay. c) The Rnase P components of the multiplex assay targets the mRNA strand 'RPP subunit p20'. Another designed probe, using the LF primer attached with a fluorophore, incorporates into the reaction as dumbbell amplicons are generated and creates a change in fluorescence as a complementary quencher is released into the bulk assay. d) The entire test can be packaged into a vacuum sealed pouch; extractions are verified for long-term storage without cold-chain dependency. The RT-LAMP assay still necessitates refrigeration. e) Detecting our multiplex assay is accomplished through a fine integration of hardware and software. The handheld device reads excited photons (480 nm Blue LED) from the bulk assay using a multi-spectra color sensor. The multi-spectra color sensor outputs 8-channels of usable RFU that can then be converted to dye/fluorophore concentration using a trained neural network (NN). Concentrations are then displayed to users via smartphone app or a provided summary tab.

Figure 2. Validation of multiplex assay using cross-reactivity and limit of detection. a) The multiplex assay used FAM and HEX fluorophores to distinguish HIV-1 and RNase P, respectively. When both targets are present in the sample, there is exponential amplification for both FAM and HEX. For samples with only RNase P, there is only amplification detected in the HEX channel. No Target Controls (NTC) show no amplification for either FAM or HEX (HIV-1 or RNase P) . b) Amplification curves using the multiplex assay to detect HIV-1 show positive detection from 10^5 down to 47 cp/reaction. The multiplex assay shows a linear performance between HIV-1 RNA and Time to Positive (T_p). The hit rate analysis for HIV-1 demonstrated a limit of detection (LOD) of 47 copies using the multiplex assay, this was established using a 95% positive ratio or higher. c) Amplification curves using the multiplex assay to detect RNase P show positive detection from 10^5 down to 351 cp/reaction. The multiplex assay shows a linear performance between RNase P RNA and Time to Positive (T_p). The hit rate analysis for RNase P demonstrated a limit of detection (LOD) of 351 copies using the multiplex assay, this was established using a 95% positive ratio or higher.

Figure 3. Validation of hardware and software of the ViraLite analyzer. a) The ViraLite analyzer is composed of several electrical components housed within a custom, 3D printed enclosure. The 480nm excitation LEDs are located on the horizontal mainboard located underneath the structural spacer and heat block. Light from these LEDs will travel vertically upward into the heat-block where PCR tubes are located with the assay. Once excited, the assay will emit photons, those are detected using the spectral color sensor located orthogonally to the path of excitation light (light path is highlighted in red). A BLE enabled MCU is located on the bottom of the mainboard PCB and connects the analyzer's components together, monitors

internal feedback, and transmits data. b) The analyzer and machine learning software (neural network) showed excellent performance detecting increasing dye concentrations (FAM and HEX). c) Last, the analyzer showed very strong agreement with the benchtop thermal cycler for analyzing both targets (HIV-1 and Rnase P) in multiplex format over a range of concentrations (10^5 down to 10 copies).

Figure 4. Clinical demonstration of ViraLite using Sensitivity, Specificity, and Semi-quantitative viral loads. a) Amplification curves from 45 clinical samples using qRT-PCR as a benchmark. A 1000 cp/mL marker is designated as a dark grey dashed line. b) Amplification curves from 45 clinical samples, analyzed using our multiplex LAMP assay on our portable analyzer (data smoothing applied with python). A 1000 cp/mL marker is designated as a dark grey line. c) Positive vs Negative comparison of qRT-PCR vs our multiplex LAMP output, displayed for all 45 samples. Positive assays are labeled in red. Negative assays are labeled in green. Positive/Negative was established using a RFU threshold of µ+3*σ. d) Clinical sensitivity and specificity of our multiplex LAMP assay with and without an internal quality control to eliminate

invalid samples. e) Viral load classification of qRT-PCR vs our multiplex LAMP assay for 45
clinical samples. The typical clinical threshold of 1000 cp/mL was used to define Above (>1000
cp/mL) and Below (<1000 cp/mL) classifications. f) LAMP T_p vs PCR C_q for all valid samples,
demonstrating a strong correlation in analysis between both methods.

Figure 5. Evaluation of survey participant feedback toward ViraLite improvements. The
percentage of participants (n = 480) for each demographic: a) Gender, b) Age, c) Income, d)
Highest Education level, e) Community, and f) Race. g) Patient responses indicated a 55.6% (HIV)
to 44.4% (PrEP) separation between current treatments. h) Percent indication of the perceived
benefits of our system from patients on either treatment (HIV – dark, PrEP – light). The highest
percentage of marked benefits were Convenience, Privacy, and Confidentiality (HIV treatment).

i) Percent indication of the potential concerns of our system from patients on either treatment (HIV
– dark, PrEP – light). The highest percentage of marked concerns were Accuracy, Guidance, and
Prescription [management] (HIV treatment).